Edwards Lifesciences In-Depth Value Research

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow large is its market ceiling? Is it enlarging an existing pie, or creating an entirely new market?6/10

  A

  Bottom line: EW's ceiling is high enough, but its essence is enlarging a large market that already exists and is still penetrating quickly, rather than creating a brand-new market from scratch. The only areas that still carry a real sense of "creating a new market" are TMTT (mitral/tricuspid transcatheter intervention) and asymptomatic/moderate aortic stenosis at the edges.

  Start with the main lane, TAVR (transcatheter aortic valve replacement). This market had already been opened in 2011 when SAPIEN first received FDA approval. What EW is doing today is pushing penetration higher and expanding indications into earlier-stage patients, not inventing demand that did not exist. The evidence is that TAVR is already the company's largest business: the report discloses 2025 TAVR revenue of 4.488 billion dollars, and I checked the official quarterly-report basis at 4.49 billion dollars, up +9.3% year over year. Growth has already fallen into the high-single-digit to low-double-digit range, which is the classic profile of a large pie that is mature, still expanding, but no longer exploding. The report itself also describes TAVR as "still expanding the market through earlier intervention, higher penetration in more countries, and treatment-process optimization," which fits "enlarging an existing pie" exactly.

  The area closest to "creating a new market" is TMTT. Mitral and tricuspid transcatheter therapies historically lacked mature devices for a long time, and EW is using PASCAL, EVOQUE, and SAPIEN M3 to open a segment with long-standing unmet clinical need and a commercial base that was almost zero. The evidence is that it is small but growing extremely fast: the report says 2025 TMTT revenue was 551 million dollars, up +56.4%, consistent with the official quarterly report's full-year TMTT revenue of 550.6 million dollars, up +56.4%. Management set a target at the 2024 investor conference for "TMTT to reach 2 billion dollars of revenue by 2030." That is turning a market that barely existed into a multi-billion-dollar category, making it the part of the EW story that most resembles "market creation." But the honest point is that this is a management target, not an achieved fact, and the report repeatedly warns that it cannot be treated directly as realized value.

  A third edge of incremental growth comes from indication expansion that creates a new patient pool "out of thin air." On May 1, 2025, the FDA approved the SAPIEN 3 platform for asymptomatic severe aortic stenosis, the first approved asymptomatic indication in the field, based on the EARLY TAVR trial (median follow-up of 3.8 years, with the TAVR group's composite endpoint of 26.8% significantly better than 45.3% in the watchful-waiting group). Bringing "patients who do not yet have symptoms" into treatment opens an additional treatable population within the existing TAVR framework. It is still an earlier-stage slice of the same aortic-valve pie, not a separate new kitchen.

  How high is the ceiling, and how firm is it? Directionally, it is very high: valvular heart disease is a serious organic disease, not discretionary consumption; global aging ensures long-term demand; and the report judges this to be "a high-barrier medical-device track with long-term growth drivers." But two gates limit the "unlimited imagination." First, TAVR volume growth must also obtain reimbursement coverage. The report checked that as of April 2026, CMS still placed TAVR under the existing NCD and CED (coverage with evidence development) framework, so FDA approval does not mean Medicare immediately pays. Second, what Baillie Gifford truly wants is a ceiling capable of "5x in 10 years." TAVR is already a mature leader growing at a low-double-digit rate; it cannot support a blue-sky case by itself, and upside optionality is heavily staked on TMTT, a new curve that is not yet profitable and not yet proven.

  In one sentence: the ceiling is high and real, but its character is "enlarging a large pie that is still penetrating + genuinely opening a market at the mitral/tricuspid edge," rather than creating an entirely new track from nothing. That is the root reason it can grow steadily but struggles to fit a Baillie-style breakout narrative.

  Jun 11, 2026
• QCan its revenue at least double over the next five years? Will growth be driven mainly by volume, price, or new businesses?4/10

  A

  Bottom line: a revenue doubling within five years, meaning roughly 12 billion dollars or more by 2030, is almost unrealistic. Based on management's own guidance and current trends, the likely five-year outcome is growth of roughly 60%–75%, not a doubling. Growth is driven almost entirely by volume; price contributes almost nothing; and the new business, TMTT, is a marginal accelerator but starts from too small a base.

  Use first-hand data to set the starting point and slope. 2025 company revenue was 6.07 billion dollars, up +11.5%; 2026 first-quarter revenue was 1.65 billion dollars, up +16.7% (about 4 percentage points were FX tailwind, with constant-currency growth of +12.7%); the company raised 2026 full-year revenue guidance to 6.5–6.9 billion dollars, implying roughly 7%–14% growth. More importantly, management's long-term framing at the 2024 investor conference is that total sales will grow at "an average annual rate of about 10%" from 2026 onward. Doubling in five years requires about 15% compound annual growth, which would mean exceeding management's own target by 50% for five straight years. That is not the base case. Compounding at 10% for five years is roughly +61%; even carrying a stronger +12% 2026-like slope for five years only reaches about +76%, still short of a doubling. The report's judgment is consistent: it explicitly says EW cannot meet the "can revenue at least double within five years" test, and its neutral scenario for expected annualized return is only 5%–7%.

  Is growth driven by volume, price, or new businesses? The answer is overwhelmingly "volume."

  Price contributes almost nothing. The report discloses that in 2026 Q1 the company said "global average selling prices were stable," and it notes in the risk factors that hospital procurement consolidation and greater customer purchasing power will pressure pricing. I checked that the official quarterly-report wording is also that TAVR global average selling prices were stable and growth came from procedure volume. In other words, EW is not relying on price increases; it is selling more valves.

  Volume is the main engine, with three legs. The first leg is TAVR penetration and indication expansion: FDA approval in May 2025 for SAPIEN 3 in asymptomatic severe aortic stenosis opens an earlier-stage patient pool, and higher penetration in more countries helps TAVR maintain high-single-digit to low-double-digit growth: TAVR +9.3% in 2025 and +14.4% in Q1. This is the largest-base, steady volume growth. The second leg is TMTT scaling: in 2025 it grew +56.4% to 551 million dollars, and the company gave 2026 TMTT guidance of 740–780 million dollars, corresponding to 35%–45% growth. It has the fastest growth, but in 2025 it was only about 9% of total revenue; even if it multiplies several times, it cannot by itself double the whole company. That is the typical limitation of a "high-growth, small-base" business. The third leg is Surgical: relatively mature, with the company guiding only mid-single-digit growth in 2026, contributing stability rather than acceleration.

  Weight the three legs together: TAVR, the largest piece, contributes roughly around 10%; TMTT grows explosively but has a low weight; Surgical drags slightly. The blended result is management's "about 10%." This explains why revenue can keep growing steadily but cannot reach a doubling: the main engine is already a mature leader with a low-double-digit slope, while the truly accelerating TMTT business is not yet large enough. Honestly, this is a high-quality company that climbs steadily through volume, but it does not realistically clear Baillie Gifford's hard five-year-doubling bar.

  Jun 11, 2026
• QAfter five years, what will take over as the next growth engine? Does this "second curve" exist today?5/10

  A

  Bottom line: the next growth engine after five years is almost certainly TMTT (transcatheter mitral/tricuspid therapy). This "second curve" already truly exists today and has begun scaling; it is not a slide in a PPT. Further out, a third curve (structural heart failure, aortic regurgitation, and other new opportunities) has also appeared, but it remains earlier-stage and more uncertain.

  Does the second curve "exist today"? Yes, and it is quantifiable. This is not a promised business; it is a real segment that is already generating revenue and is disclosed independently. Evidence: in 2025, TMTT revenue was 550.6 million dollars, up +56.4%; in 2026 Q1, TMTT revenue was 173 million dollars, about +42% (the report text says +51.9% for Q1, but the official quarterly report and multiple media sources use about 42%, so I use the official figure here). It has a real approved/in-market product portfolio: PASCAL (mitral/tricuspid repair), EVOQUE (tricuspid replacement), and SAPIEN M3 (mitral replacement). It is not a concept. The company gave 2026 TMTT guidance of 740–780 million dollars, corresponding to 35%–45% growth, and stated at the 2024 investor conference that "TMTT will reach 2 billion dollars by 2030." In other words, the successor does not need to be born five years from now; it is accelerating right now. The job five years from now is to grow from a "small high-growth business" into a large business with meaningful profit contribution.

  Why will it be the successor rather than something else? The platform-compounding logic is smooth. TAVR is already a mature main lane growing at a low-double-digit rate (+9.3% in 2025), and cannot alone provide the next leg of upside. TMTT lets EW reuse its existing clinical-evidence system, operator-training network, sales and intraoperative support across about 100 countries, and apply them directly to the long-unmet new track of mitral/tricuspid disease. The report's view that "PASCAL, EVOQUE, and SAPIEN M3 give EW an opportunity to reuse its existing clinical, sales, and training system in a new track" captures the strongest underlying logic of this second curve: channels and evidence are shared, so marginal expansion cost is relatively low.

  The third curve has appeared, but it is further away and less concrete. At the investor conference, the company clearly divided future drivers into three layers: "continued TAVR expansion, rapid TMTT scaling, and new opportunities such as structural heart failure and aortic regurgitation." The report also lists "structural heart failure and aortic regurgitation" as later potential increments. That means the true successor after five years is TMTT, while the next baton after that (structural heart failure/AR) is today only an R&D and early-clinical reserve. Whether it materializes remains uncertain and should not be included in the base case.

  The honest risk warning: "exists" does not equal "delivered." The core question for the second curve is profit, not revenue. The report repeatedly stresses that the hardest part is for TMTT to move from a "small high-growth business" to a "large high-return business," and that investors need to track actual penetration, complications, and whether gross margin can improve with scale. The company has not separately disclosed enough detail to show whether TMTT's gross margin and unit economics have already reached mature TAVR levels. So the conclusion is: the successor has been chosen, exists, and has started running. EW is one of the few names that truly has the "second curve" Baillie Gifford wants to see. But whether this curve can move after five years from "can grow" to "can make money" remains the most important and least proven wager in the investment.

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  Bottom line: EW's core competitive advantage is not "lowest cost," but "most trusted outcomes." Its compound moat is woven from depth of clinical evidence, physician proficiency, regulatory barriers, brand trust, and switching costs embedded in hospital workflows. Over the next three to five years, my judgment is that the TAVR moat is "stable and slightly wider," while the TMTT moat is "being built from scratch and not yet fully formed." The overall trend is steady with some improvement, but it is not invincible and will not widen monotonically.

  First define what the moat actually is. EW does not win through low price. The report explicitly rates its cost advantage as "weak"; this is a "high gross margin, high evidence, high support" model. The real barriers come from four stacked pieces. First is data/clinical evidence: the EARLY TAVR trial became the basis for approval in asymptomatic patients, and 7-year PARTNER 3 data continues to support comparable long-term outcomes between TAVR and surgery. Competitors cannot quickly replicate this evidence base accumulated over more than a decade. Second is regulatory barrier: valve products are subject to frequent inspections by the FDA and European notified bodies and to ISO 13485 quality-system constraints; the FDA's May 2025 approval of SAPIEN 3 for the new indication of asymptomatic severe aortic stenosis further raises the bar. Third is switching cost, which the report rates as "medium-high": routine operating-room presence by field clinical specialists, hospital program buildout, operator training, and real-world evidence mean changing devices is not as simple as "changing suppliers." Fourth is brand: the company calls SAPIEN the "category leader," and in physicians' minds it represents predictable outcomes. These four pieces share one feature: they protect "whether physicians are willing to keep using it," not merely "whether the device can be manufactured."

  How deep is the moat, and how long would it take rivals to copy it? The report infers that replicating a similar moat would require years of clinical trials, investment at the several-billion-dollar level, global regulatory approvals, and hospital-education networks. The difficulty is the closed loop of "evidence + training + reimbursement," not manufacturing. The competitive landscape confirms this: EW itself lists a concentrated set of rivals in its 10-K: TAVR mainly faces Medtronic and Abbott, while TMTT mainly faces Abbott. The profit pool has not scattered across countless players, which shows the barriers are real.

  Will it widen or narrow over the next three to five years? This needs to be split by business and timing; a single elevated sentence would blur the truth.

  On the TAVR side: stable and slightly wider, but rising maturity is itself a double-edged sword. The positives are that the asymptomatic indication expands the treatable population, while brand and evidence keep accumulating. In 2026 Q1, EW also saw share rebalancing from a European competitor's exit and a "slightly improved" global TAVR competitive position. But caution is needed: the more mature TAVR becomes, the closer it gets to a steady state in which "three strong players struggle to pull meaningfully away from each other." Share improvement may not be permanent. Competitors' long-term data is also being updated, and the report notes that ACC in 2026 mentioned Medtronic communicating with physicians about Evolut long-term reintervention rates (according to the report). Long-term evidence such as durability/reintervention rates is one of the few variables that can truly erode the moat if it turns. So the TAVR moat is "stable and somewhat wide," not "continuously widening."

  On the TMTT side: the moat is "under construction" and not yet formed. EW has not yet established the mature evidence-training-reimbursement loop in TMTT that it has in TAVR. Moat width depends on whether PASCAL/EVOQUE/SAPIEN M3 can replicate that success. Abbott is also strong in mitral disease. This line is the place where the moat is most likely to "substantially widen" over the next three to five years, but it is also the most uncertain.

  In one sentence: the core advantage is a compound of "trusted outcomes + embedded clinical support + regulatory/evidence barriers." It is deep enough, and its most important component is trust, not cost. Over the next three to five years, the direction is modest improvement within stability: TAVR can be defended and TMTT may widen, but "share ceilings from maturity" and "long-term durability-data risk" mean it will not widen monotonically. The honest moat rating is "deep but not invincible."

  Jun 11, 2026
• QIf the core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?5/10

  A

  Bottom line: EW has the DNA to iterate within the large structural-heart platform, but it lacks strong evidence that it can jump outside its lane and completely reinvent itself if the core business is disrupted. Its attitude toward mistakes and bad news is quite candid: it records impairments when they are due, discloses litigation when it exists, and does not use storytelling to hide the cost. The former is a mild positive, and the latter is a clear positive, but neither reaches the regenerative DNA that Baillie Gifford values most: surviving the disruption of the core business and being reborn.

  First, how should "reinvention DNA" be tested? What Baillie Gifford really asks is: if one day TAVR is disrupted by some entirely new therapy, can this company find another life? That requires looking at how it has historically responded when a core business disappeared or shifted. EW's strongest positive evidence is proactive "self-narrowing + refocusing": in September 2024 it sold the Critical Care business to BD for 4.2 billion dollars (closing on September 3, 2024), generating the report's cited after-tax disposal gain of about 3.3 billion dollars, and actively rebuilt itself as a "pure structural-heart platform." This shows management is willing to make trade-offs for focus and is not attached to legacy businesses. It is evidence of a willingness to "actively reshape the portfolio."

  But two things must be separated honestly: "changing growth engines within the same field" is not the same as "crossing into a new field after the core is disrupted." EW's demonstrated regenerative ability has mainly occurred inside the same broad structural-heart platform: from Surgical surgical valves, to TAVR transcatheter aortic valves, to TMTT mitral/tricuspid therapies. It continually reuses the same clinical-evidence, operator-training, regulatory, and sales network into adjacent tracks. That is real platform-extension ability (the report judges that PASCAL/EVOQUE/SAPIEN M3 let it reuse its existing system in new tracks), but its "reinvention" has never left the center of gravity of "cardiac valve intervention." If disruption came from outside that center, such as a drug or gene therapy that fundamentally reduced the need for valve replacement, EW has no historical record of "leaving devices and starting a new game." The report also implies this: it describes the source of industry disruption as "better devices and better clinical evidence," meaning disruption is likely to remain within the field, and EW's response is to defend through stronger evidence and product iteration, not to transform completely. So the regenerative DNA is "strong within the platform, unproven across platforms."

  Next, how does it handle mistakes and bad news? On this dimension, EW performs clearly well. It does not avoid failed capital actions: after the proposed JenaValve acquisition was blocked by the FTC, the company honestly recorded about 99.8 million dollars of impairment on the JenaValve bridge loan in 2025 (the Q4 release also disclosed a 99.8 million dollar impairment loss), plus about 146.9 million dollars of investment/option-related impairments and about 40 million dollars of intangible-asset impairment. In the same year it also actively disclosed large intellectual-property litigation expenses, an IRS tax dispute, and securities class-action litigation. The report's judgment is that "management is fairly candid... compared with many companies that tell stories without discussing the cost, this deserves recognition." In other words, when bad news arrives, EW tends to put the cost on the table rather than polish it away with adjusted metrics. That is exactly the honest culture Baillie Gifford appreciates.

  Put the two sides together: EW has an iteration gene of "active focus and changing engines within its field," and it has an honest culture of "facing mistakes and recording/disclosing impairments truthfully." Both make it more credible than the average company when bad news comes. But it lacks evidence of cross-domain rebirth after an externally disrupted core; its regenerative resilience is bounded by the single center of structural heart disease. For Baillie Gifford's "reinvention" question, the honest conclusion is: solid internal capability and an honest culture, but the extreme resilience of a true rebirth has not been proven. This is mildly positive, not a high score.

  Jun 11, 2026
• QDoes management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profits for the next five to ten years?4/10

  A

  Bottom line: EW's management is a reliable, professional, career-manager team whose compensation is highly linked to performance/share price, and it is indeed willing to sacrifice current profit for growth five to ten years out. But it is not a founder-led company, and the degree of "net-worth alignment" between management and shareholders is only moderate. Aggregate executive ownership is extremely low, so alignment is directionally right but limited in force. EW does not have Baillie Gifford's favorite trait: founders heavily invested and breathing with the company.

  First, the evidence for "long-term view + willingness to sacrifice current profits" is fairly strong. The clearest evidence is that EW keeps putting a large share of current profit into R&D and clinical evidence rather than protecting a prettier margin. The report discloses that 2025 R&D spending was about 18% of sales, much of it used for clinical trials, regulatory submissions, and real-world evidence collection. 2025 GAAP operating profit even fell from 1.379 billion dollars in 2024 to 1.264 billion dollars, partly because of continuing personnel, clinical, and litigation investment. More symbolically, in September 2024 it sold Critical Care to BD for 4.2 billion dollars, voluntarily giving up a mature cash business in exchange for long-term focus as a "pure structural-heart platform." That is a typical trade-off of sacrificing near-term scale for long-term positioning. Add to that continuous spending on TMTT, the second curve targeted to scale to 2 billion dollars by 2030, and the conclusion is that management's decision clock runs in years, not the next quarter. This is consistent with the report's "target holding period of more than 10 years" and its view that value will be realized across multiple product platforms over time.

  Now alignment of interests: the direction is correct, but two facts limit the force.

  On the positive side, compensation is highly linked to share price/performance. Citing the Proxy, the report says that 93% of the CEO's 2025 target total compensation was at risk and 81% was long-term incentive; over the past five-year average, 92% of the CEO's target total direct compensation was performance-related and 79% was tied to share-price performance. The company also has mandatory shareholding requirements: the CEO must hold stock equal to 6 times base salary, and other executives 3 times salary. In 2025, say-on-pay received about 88% support, reflecting broad shareholder approval of the compensation plan. This structure means that if management damages the share price, its own pay is materially hurt. The incentive direction is right.

  But the negative side is important: absolute ownership is very low, with no founder-style "same net worth." Citing the Proxy, the report says that as of January 31, 2026, all current directors and executives together owned only about 1.805 million shares, or 0.31% of total shares; the CEO's direct and attributable shares totaled about 345,800, or less than 1%. In a company with a market cap of about 49.5 billion dollars (at a current share price of about 86 dollars and market cap of about 49.5 billion dollars), this ownership is small relative to both personal compensation and company scale. The report's wording is apt: "this is not a negative red flag, but it also means management is not completely breathing with ordinary shareholders the way some founder-led companies do." Baillie Gifford LTGG repeatedly stresses that founders/stewards should be deeply bound to shareholders and willing to make long-term bets. EW is "career managers aligned by system," not "founders staking their net worth." That is why it cannot reach the top tier on this question.

  Capital allocation alignment also has two sides. The positive is ongoing buybacks reducing share count: the report says diluted weighted shares fell from 631.2 million in 2021 to 585.8 million in 2025, with about 899 million dollars repurchased in 2025. I checked that in August 2025 the company added another 500 million dollars of accelerated share repurchase and had repurchased more than 800 million dollars year to date, while adding authorization. But the M&A record is not perfect: after JenaValve was blocked by the FTC, EW recorded about 99.8 million dollars of impairment. The report therefore judges EW to be an "aggressively attacking large company, not an extremely cautious allocation machine that almost never makes mistakes."

  In sum: management has a clear long-term view and proves through real actions, such as selling a business and pressing profits down to fund R&D, that it is willing to sacrifice today for the future. The compensation system also ties their wallets to the share price. But "founder heavy ownership and deep same-net-worth alignment with the company" is absent at EW; aggregate executive ownership of 0.31% is a hard fact. The honest conclusion is: long-termism yes, institutional alignment yes, founder-level deep binding no. Overall, this is trustworthy but not full-score shareholder orientation.

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth sustainable and not dependent on harming society or exploiting regulation?6/10

  A

  Bottom line: if EW disappeared tomorrow, patients, heart teams, and hospitals would miss it a great deal. Its products directly affect survival and quality of life for patients with severe valvular disease, and they are embedded in hospital clinical workflows. At the same time, its growth model is highly sustainable and barely depends on social harm or regulatory arbitrage. It has a positive structure in which the more society benefits and regulators recognize it, the more it grows. On this question, EW is one of the few companies that stands firmly on both sides.

  First, how much would customers miss it? Its indispensability is high, at the level of clinical necessity. It is not selling optional discretionary consumption; it sells implantable devices for treating severe aortic stenosis and mitral/tricuspid disease. This indispensability is supported by hard evidence: the EARLY TAVR trial showed that in asymptomatic severe aortic-stenosis patients receiving TAVR, the composite endpoint of death/stroke/unplanned cardiovascular hospitalization was 26.8%, significantly lower than 45.3% in the watchful-waiting group. It materially reduced death and stroke risk. In other words, without EW's products, some patients would lose what is currently the best and most evidence-rich treatment option. The report also emphasizes that demand is "highly rigid" and addresses "patients with severe valvular disease, not optional discretionary consumption."

  This "being missed" is not only at the product level; it is also at the workflow level, which is the root of high switching costs. EW does not sell the device and leave: its field clinical specialists routinely enter the operating room, provide operator training, support hospital structural-heart program buildout, and collect real-world evidence. The report judges that this embedding means "replacing the device is not as simple as changing suppliers," and that switching costs are "medium-high." So if EW disappeared tomorrow, hospitals would lose not only a valve model, but an entire clinical-support system with trained physicians and smoothed workflows. It would be hard to replace seamlessly in the short term. That is the part of EW that most resembles "being missed."

  But one honest caveat is needed: the competitive landscape discounts the degree of being missed. EW is not the only supplier. TAVR also has Medtronic and Abbott, and TMTT also has Abbott, all strong competitors. Patients would not be "left without medicine"; substitutes exist. What is truly hard to replace is "the short-term convenience of EW's combination of evidence + brand + proficiency," not the treatment category itself. That makes the degree of being missed "high, but not monopoly-style irreplaceable."

  Now, is growth sustainable and not dependent on harming society or regulation? This is the cleanest part of EW's quality, and it passes both tests.

  First, social sustainability: its growth aligns with social benefit rather than profiting from social costs. Each additional valve EW sells corresponds to treatment of a severe valvular-disease patient and a lower risk of death/stroke. Faster growth means more patients treated. This is sharply different from businesses that expand through addiction, information arbitrage, or shifting externalities. The report characterizes the demand as "severe and long-lasting medical need," and aging ensures that demand grows naturally rather than through artificial stimulation.

  Second, regulatory sustainability: its growth comes from "passing regulation," not "bypassing regulation." EW's moat itself is built on regulatory barriers: its products are subject to frequent inspections by the FDA and European notified bodies and to ISO 13485 quality-system requirements. The latest incremental growth comes precisely from positive regulatory recognition: the FDA's May 2025 approval of SAPIEN 3 for asymptomatic severe aortic stenosis legally brings earlier-stage patients into treatment. Regulation is not the enemy of its growth; it is the starting gun. The only sustainability constraint is not "whether it is compliant," but "the pace of reimbursement." The report checked that as of April 2026, CMS still placed TAVR under the existing NCD/CED framework, so FDA approval does not mean Medicare immediately pays in full, and commercial scaling will be constrained by the pace of reimbursement policy. But this is a question of "how fast volume ramps," not "whether the growth method is legitimate."

  Overall: customers, especially patients and heart teams, would miss it greatly because it concerns life and death and is embedded in workflows. Strong competitors mean it is not monopoly-style irreplaceable. Its growth model is clean and sustainable across both social and regulatory dimensions: saving lives is growth, and passing regulation is volume growth. EW gives a rare "passes both" answer to Baillie Gifford's double question, and this is one of the most reassuring parts of its quality.

  Jun 11, 2026
• QWhat are the unit economics of this business (gross margin, incremental returns)? Do they improve or worsen with scale? Where does the money it earns go?7/10

  A

  Bottom line: EW's unit economics are excellent. Gross margin has stayed above 80% for a long time, reflecting structurally high profitability rather than cyclicality. As scale grows, economics generally move "stable to better" (the sales/clinical/regulatory platform has scale effects), but there is one offsetting variable: to promote still-immature TMTT and internationalization, the company is willing to hold operating margin in the high-20% range, so near-term "incremental returns" are deliberately diluted. The money it earns mainly goes to R&D and clinical investment + share repurchases + M&A, not dividends.

  Start with gross margin and profitability: the quality is hard, and it is structural. The report discloses that 2025 continuing-operations gross margin was about 80.5%, basically stable in the 80%–81% range during 2023–2025. I checked the continuing-operations cost structure in the company's 2025 10-K, and it is consistent with this (note: the company's earnings release separately gives "adjusted gross margin of about 78%–79%," which is a different basis with different exclusions; the two are not contradictory). The report judges that this "looks more like support from product mix, technology barriers, and brand/evidence advantage than a cyclical accident." In other words, the 80% gross margin is a structural advantage, not cyclical windfall. That is decisive for unit economics.

  Operating margin is the result of "active management," revealing the truth about incremental returns. 2025 GAAP operating profit fell from 1.379 billion dollars in 2024 to 1.264 billion dollars, but the main reasons were large litigation expenses, about 99.8 million dollars of JenaValve impairment, and other one-off items, not a worse business. More telling is that 2026 Q1 operating margin was about 29%, and the company guided full-year operating margin to remain at 28%–29%. Note that with an 80% gross margin, EW could produce a higher operating margin, but it chooses to reinvest the difference in R&D (about 18% of sales), clinical trials, and TMTT commercialization. This means that as scale grows, it has not allowed margins to rise sharply; it is reinvesting incremental economics into the second curve. This is the trade-off of sacrificing current margin for the long term, and it explains why its near-term "incremental return" is flattened deliberately.

  Do unit economics improve or worsen as scale grows? The direction is "stable to better, but partly offset by reinvestment." The improving side: R&D, clinical trials, regulatory submissions, and the sales/operator-training platform across about 100 countries all have scale effects. The same evidence and channels can be reused in TMTT, making marginal expansion cost relatively low; the report calls this "platform compounding." The worsening/dilutive side: TMTT is still early in commercialization, and the report repeatedly warns that the hardest part is for it to move "from a small high-growth business to a large high-return business." Whether its gross margin and unit economics can reach mature TAVR levels has not been disclosed in sufficient detail. To push it, the company deliberately holds down overall margin. So the honest conclusion is: mature core businesses (TAVR/Surgical) see mild unit-economic improvement with scale, but the ramp-up period of new businesses will drag on overall incremental returns. The net effect is "excellent, but not quickly becoming prettier."

  Returns on capital: excellent, but not top-tier. The report roughly estimates ROE at about 10%–11% on a 2025 continuing-operations basis and ROIC probably in the mid-teens (not directly disclosed by the company, so this is an inference). ROE is held down by a large net-cash position (as of 2025 year-end, cash and short-term investments were about 4.226 billion dollars, while long-term debt was only about 598 million dollars, making it clearly net cash). The report judges that "returns on invested capital are still excellent, but not as effortlessly beautiful as some top-tier medical-device leaders, because it keeps investing heavily in R&D and clinical evidence." I agree with that characterization: a high reinvestment rate buys long-term growth at the cost of current capital efficiency.

  Where does the money go? Three destinations, with no dividend. First, reinvestment in R&D and clinical work (about 18% of sales), which is the source of the moat. Second, share repurchases: the report says EW repurchased about 899 million dollars in 2025, and diluted shares fell from 631.2 million in 2021 to 585.8 million in 2025. I checked that the company added another 500 million dollars accelerated share repurchase in August 2025, with more than 800 million dollars repurchased year to date and new authorization added. Third, M&A: Innovalve, Endotronix, and others, while JenaValve being blocked and impaired shows M&A is not all good. The report notes that EW has never paid a cash dividend and retains cash for the business. The "wisdom" of the buybacks needs an honest reservation: many repurchases occurred in the 70–80-plus dollar range, and based on current intrinsic-value estimates, they were not necessarily done at a large discount. The report rates them as "steady and helpful, but not outstanding allocation."

  In one sentence: unit economics are those of an excellent student with "structurally high gross margin + scale effects," but EW deliberately uses heavy reinvestment to keep current margins and capital returns at "excellent but not top-tier" levels, putting money into the R&D moat and share count reduction, and betting on compounding over 10 years. This aligns with Baillie Gifford's preference, but the ideal flywheel of "incremental returns rapidly improving with scale" has not yet shown up because TMTT is still ramping.

  Jun 11, 2026
• QWhat conditions must all hold for it to rise 5x in 10 years? Are those conditions realistic? What expectations are embedded in today's share price?2/10

  A

  Bottom line: for EW to rise 5x in 10 years, a stringent chain of conditions must all hold at the same time: revenue compounding at about 13% (far above management's self-set roughly 10%), TMTT truly becoming a large profitable business, margins not being diluted over the long term, and the market still granting it a valuation multiple above ordinary medical devices 10 years from now. Each condition on its own is not absurd, but a 5x outcome requires all of them to happen together, so the realistic probability is low. Today's share price of about 86 dollars already embeds a fairly optimistic expectation of "healthy TAVR growth + TMTT delivery + no long-term premium compression." The report judges the current price to be roughly in its optimistic-scenario range, with insufficient margin of safety.

  First translate "5x" into hard conditions. A 5x return over 10 years is about 17.5% annualized share-price return. Share-price return = per-share earnings/owner earnings growth × valuation multiple change (plus a small boost from buybacks reducing share count). So a 5x outcome needs the following conditions to hold "simultaneously":

  Condition one: revenue and earnings growth must be materially higher than current reality. EW currently has low-double-digit revenue growth: +11.5% in 2025, and 2026 revenue guidance of 6.5–6.9 billion dollars with adj EPS of 2.95–3.05. Management's own long-term wording is "about 10% average annual growth". If the valuation multiple is unchanged after 10 years, earnings growth of about 10% gets to only about 2.6x, far short of 5x. To reach 5x, earnings need to compound about 13%–15% plus buyback help, meaning the company must outperform management's target for 10 straight years. This is the first and hardest hurdle.

  Condition two: TMTT must mature from a "small high-growth business" into a "large high-profit business." In 2025, TMTT was only 551 million dollars, about 9% of total revenue, and the company's target is to reach 2 billion dollars by 2030. The 5x narrative depends heavily on this second curve not only scaling volume, but also generating meaningful profit. The report repeatedly stresses that the hardest step is "from a small high-growth business to a large high-return business." This is a target, not a fact.

  Condition three: TAVR indication expansion must translate into real reimbursable procedure volume. FDA approval in May 2025 for asymptomatic severe aortic stenosis opened the patient pool, but the report checked that as of April 2026, CMS still placed TAVR under the existing NCD/CED framework. FDA approval ≠ Medicare payment. If reimbursement coverage does not keep up, volume cannot ramp.

  Condition four: margins cannot be depressed for the long term. The company guides operating margin to remain at the high end of 28%–29%. If pushing TMTT and internationalization keeps margins lower for a long time, per-share earnings growth will be dragged down, making 5x harder.

  Condition five: the market must still grant a high premium after 10 years. This is the most hidden condition. EW's current static GAAP PE is about 47x (TTM EPS of 1.88 dollars and share price of about 86 dollars, with the report using 46.6x). Even if earnings multiply over 10 years, if the multiple falls from 47x back toward the industry center, valuation compression will consume a large part of the share-price gain. The report explicitly warns that "if the market merely sees EW as an ordinary high-quality medtech company, multiple compression from high levels is enough to swallow a large part of operating progress." In other words, 5x requires not just good performance, but also the market not "waking up" for 10 years and taking back the premium.

  Are these conditions realistic? One by one, they are not absurd: TAVR is a real leader, TMTT is a real curve, and the moat is real. But "all five holding simultaneously" is a low-probability product. The report's intrinsic-value framework quantifies this clearly: it gives a fair intrinsic-value range of 68–82 dollars and an optimistic range of 82–98 dollars, while the optimistic case embedded in a 5x narrative (owner earnings starting around 1.65 billion, growing 8% for the first 10 years, with terminal growth of 4%) still produces only about 96 dollars per share of value. In other words, under the report's own DCF, even if the optimistic assumptions nearly all materialize, the value corresponds roughly to the current share price. It does not produce room for "another 5x from today" at all. That is exactly why the report's final rating is Watch, not Buy.

  What expectations are embedded in today's share price? It embeds that "a fairly optimistic scenario has already been prepaid." The current price of about 86 dollars sits in the middle of the report's optimistic range (82–98 dollars), about 15%–20% above the roughly 75 dollar midpoint of its fair range. Owner earnings/FCF yield is only about 2%–3%, clearly below the roughly 4.5% risk-free yield on the 10-year Treasury. This means the market has already priced in the good outcome of "TAVR remains healthy, TMTT delivers, margins hold, and the long-term premium does not compress." Buying today means you earn money from "all those conditions coming true," with almost no cushion if only part of them comes true.

  In one sentence: 5x in 10 years requires about 13%+ compound earnings growth, TMTT profitability, reimbursement coverage catching up, margins not collapsing, and the market not taking back the premium for 10 years. All five things must hold together. Each is credible, but the combined probability is not easy. Today's share price has already priced in the fairly optimistic script, leaving thin odds for "5x." This is a good company worth long-term tracking, but "5x in 10 years" looks more like an upper-bound scenario requiring everything to go perfectly than a base expectation.

  Jun 11, 2026
• QWhy has the market not realized all this yet? Is it hard to understand, disdained, or too far out? What would become the "narrative inflection point"?3/10

  A

  Bottom line: for EW, this question needs to be answered in reverse. The market has not "failed to realize how good it is"; it realized it long ago and has fully, perhaps even somewhat over, priced it in. EW is not misunderstood and not disdained. If anything remains not fully "seen," it is in a direction unfavorable to bulls: the market may be underestimating the uncertainty of TMTT delivery and the fragility of a high valuation multiple itself. The true "narrative inflection point" is therefore two-sided: upward inflection requires TMTT profitability or a reimbursement breakthrough, while downward inflection comes from growth deceleration or a reversal in durability data.

  First, prove the reversed premise that "the market already realizes it." Baillie Gifford's question assumes there is a perception gap and that a good asset is being ignored. But EW's valuation itself is hard evidence that the market highly recognizes it. Current static GAAP PE is about 47x (TTM EPS of 1.88 dollars and share price of about 86 dollars, with the report using 46.6x), forward PE is about 28.5x, far above the medical-device industry forward PE median of about 19.8x. The report's relative valuation also shows EW's PE/P-FCF far above peers such as Abbott, Boston Scientific, and Medtronic. The market is willing to give it a 60%–100% premium for being a "pure structural-heart platform." That is not "hard to understand"; it is precisely "well understood and highly paid for." The report summarizes the bear case sharply: "EW may be a company so good that everyone already knows it is good, and that is exactly why the stock is no longer cheap." So among the three choices (hard to understand/disdained/too far out), the first two do not hold.

  What about "too far out"? The direction is the opposite and unfavorable to bulls. If there is anything the market has not fully seen, it is more likely that it is "looking too far out and pricing uncertain long-term optimism too early," rather than "not seeing the upside." Evidence: the current price implies an owner earnings/FCF yield of only about 2%–3%, below the roughly 4.5% 10-year Treasury yield. The report judges that the current price of about 86 dollars sits in its optimistic-scenario range, about 15%–20% above the roughly 75 dollar midpoint of the fair range. In other words, the market has already priced in the good script of "healthy TAVR + TMTT delivery + margins holding + no long-term premium compression." What is less fully reflected is downside risk: the execution risk that TMTT's hardest step is "from a small high-growth business to a large high-return business," and the damage from multiple compression if the market later reframes EW as an "ordinary high-quality medtech" company. The report notes that in 2025 EW already had large litigation expenses and about 99.8 million dollars of JenaValve impairment, showing that "perfect execution" is not the base case. This layer of "imperfection" may not be fully absorbed by optimistic pricing.

  Since it is fully priced, the "narrative inflection point" must be viewed in both directions. This is especially important for Baillie-style one-sided optimism.

  Upward narrative inflections, meaning events that would "prove" the high valuation reasonable or even open new upside: first, TMTT moves from "can grow" to "can make money." If PASCAL/EVOQUE/SAPIEN M3 penetration accelerates, gross margin and cash flow improve visibly, and the business tracks toward the 2030 target of 2 billion dollars, the market would be willing to assign more value to the second curve. That is the most meaningful upward inflection. Second, a reimbursement breakthrough: if CMS brings earlier/broader indications, such as asymptomatic severe AS, into clearer Medicare coverage and turns the FDA-approved asymptomatic indication into truly reimbursable procedure volume, TAVR's ceiling would be materially raised.

  Downward narrative inflections, meaning events that would collapse the high premium and cause permanent loss: first, TAVR growth falls significantly into low-single digits for multiple consecutive quarters and stays there for more than two years. Once the mature core loses speed, the "high-premium growth stock" label gets stripped away. Second, core products develop long-term durability/reintervention/safety controversies. The report notes that ACC in 2026 mentioned Medtronic communicating with physicians about Evolut long-term reintervention rates (according to the report). This kind of long-term data is one of the few variables that can truly change physician preference and shake the moat. Third, TMTT still has not formed meaningful profit contribution around 2028, or the company keeps using expensive acquisitions to buy growth and creates more impairments. Any of these could move EW from a "high-quality, high-valuation growth stock" into an "ordinary device stock whose growth is insufficient to support its valuation." The report judges this to be the largest permanent-capital-loss scenario: the business remains good, but not good enough for today's price.

  In one sentence: this is not a "cheap good company the market does not understand," but a "good company the market understands and has fully priced." The real inflection is not "when the market discovers its quality," but whether "TMTT/reimbursement can deliver enough to support the current premium (upside)" or "growth/durability reverses and forces multiple mean reversion (downside)." To Baillie Gifford's three questions of hard to understand/disdained/too far out, EW's honest answer is: none of the above. It is understood, liked, and possibly viewed too optimistically, so the current setup is better suited to waiting for a downward inflection that creates better odds than chasing a perception gap that does not exist.

  Jun 11, 2026